BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Cuts Target Price to $13

Futu NewsJan 7 20:36 · Ratings

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaJan 4 05:05

Clear Street Launches Healthcare & Biotechnology Equity Research

BusinesswireDec 18, 2024 03:00

Bristol Myers Squibb Terminates Agreements With Immatics Due To Ongoing Portfolio Prioritization Efforts Within BMS For Allogeneic Programs; Collaboration With BMS Under The 2019 Multi-Target TCR-T Strategic Collaboration Agreement Remains Ongoing

BenzingaDec 16, 2024 22:42

Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16

Futu NewsDec 16, 2024 19:31 · Ratings

Immatics N.V. Reports Strong Q3 2024 Progress and Financials

TipRanksNov 26, 2024 11:57